Prof A Suhrbier is the Group Leader of the Inflammation Biology Group at the Queensland Institute of Medical Research. The group focuses at the applied end of inflammation research and development and will be involved in the identification and development of new interventions and diagnostics for inflammatory diseases and cancer, often in collaboration with the biotech industry.
Most common diseases of ageing like diabetes and cancer have proven intractable because much of our knowledge is limited to individual molecules. This proposal takes a global approach to complex diseases, utilising quantitative high-resolution methods and computational modelling. This research will lead to a completely new way of thinking about complex diseases providing a range of completely novel treatment options.
Breast cancers have diverse characteristics such as their response to treatment and their propensity to relapse. We know that the individual suit of oncogenic lesions probably influences diversity but the characteristics of the cell type from which the cancer arose probably also plays a part. This Application addresses this question and investigates a major new discovery made by the applicant that the ets transcription factor Elf5 plays a key role in specifying the diversity in breast cancer.
New Antibiotics And Treatment Methods Against Drug-resistant Bacteria
Funder
National Health and Medical Research Council
Funding Amount
$766,468.00
Summary
Infectious disease is a leading cause of death, and the emergence of "superbugs" in the community and hospitals is of grave concern. We are developing new, powerful antibiotics that can kill superbugs using ‘forgotten’ drugs from the 1970s. These will combat bacteria that cause pneumonia, skin and urinary track infections; diseases that cause death and discomfort for thousands of Australians today. We will also develop methods to directly remove bacteria from blood infections.
Novel Endocrine Approaches To Diagnosis & Treatment Of Men With Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$926,980.00
Summary
Most men are diagnosed with localised prostate cancer, others have advanced disease. Vision: Identify how tumours are insignificant vs aggressive (Aim 1.1 & 1.2). Predict which tumours will progress to incurable disease (Aim 1.3) and how to target them (Aim 1.4). Discover how each patient tumour is different (Aim 2.1) and pre-clinically test new therapies (Aim 2.2). Outcomes: practice changing discoveries that identify novel therapeutic targets & biomarkers improving diagnosis and treatment.
In patients predisposed to metabolic diseases, excessive fats get delivered to various tissues. About 10 to 15% are converted into sphingolipids, many of which have deleterious effects on tissue function. Blocking sphingolipid production prevents diabetes and most cardiovascular diseases in rodents. We seek to better understand these mechanisms and determine how the observations can be translated into new therapies and better clinical outcomes.
How The Bcl-2 Protein Family Controls Apoptosis And Impacts On Cancer Development And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$850,346.00
Summary
Impaired cell death (apoptosis) is now recognized as an important step towards cancer and a major barrier to effective therapy. The discoveries on apoptosis by Professor Jerry Adams and colleagues have galvanized the search for drugs that engage the cell’s apoptotic machinery as a new way to treat cancer. His proposed studies aim to clarify how apoptosis is controlled and how the control goes awry in cancer, and to determine how such drugs can be most effectively used to improve cancer treatment ....Impaired cell death (apoptosis) is now recognized as an important step towards cancer and a major barrier to effective therapy. The discoveries on apoptosis by Professor Jerry Adams and colleagues have galvanized the search for drugs that engage the cell’s apoptotic machinery as a new way to treat cancer. His proposed studies aim to clarify how apoptosis is controlled and how the control goes awry in cancer, and to determine how such drugs can be most effectively used to improve cancer treatment.Read moreRead less
Prof. Simes will lead and develop research at the NHMRC Clinical Trials Centre in collaboration with major national and international cooperative groups. Research themes include integrating molecular science with trial design and embedding research routinely in health care. Projects include surgery for rectal cancer; novel targeted therapy in gastric cancer; aspirin to prevent colon cancer; placental transfusion for preterm babies; risk in heart disease; economic assessment of clinical trials.
The identification, prevention and management of chronic disease risk factors and understanding impact on clinical outcomes is fundamental to improving health and well-being. The program of work encapsulated in this application utilises a number of research methods to advance our understanding and provide new directions for cardiovascular disease prevention and management.
Meta-research: Using Research To Increase The Value Of Health And Medical Research
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
Improving the return on investment in health and medical research will produce more and faster discoveries that enhance the lives of all Australians. Many problems in the research process are well known and have been pervasive for decades. I will use the research process to improve the research process. I will improve Australia's health and medical research workforce and the quality of the research they produce, creating benefits in multiple fields that last long into the future.